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1esearch Recommendations
uring the Writing of White Papers
nformative white papers such as that of Becker et al. (1) are often
elpful, although they could assist practitioners further by suggest-
ng that clinical trials could and should be done when there is a
easonable consideration. For example, although the authors and
thers (2) state that there is no reported high-quality, evidence-
ased information concerning the use of bridging dose low-
olecular-weight heparin when platelet antagonist therapy is to be
educed or interrupted, rather than just summarily dismissing the
oncept of using anticoagulant medications such as bridging dose
ow molecular weight heparin, this type of summary or editorial
iece would be a fine place to recommend that perhaps low-
olecular-weight heparin should be studied for just such use. The
ssue in this case is the statement: “Bridging with anticoagulants
as a substitute for platelet antagonists), given the absence of
upportive data, does not have a place in periprocedural patient
anagement.” The use of bridging dose low-molecular-weight
eparin in exactly this circumstance would seem reasonable and is
he standard format when warfarin therapy must be interrupted. In
act, instead of reducing the extent of anticoagulation with the
iscontinuation of the platelet antagonists clopidogrel or prasugrel,
ridging dose low molecular weight heparin just might be the
reatment of choice in exactly this circumstance. Appropriate
esearch might confirm such a consideration, and white papers
uch as these might encourage that the relevant research be done
ather than simply stating or just repeating that such treatment
hould not be recommended.
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e very much appreciate the comments of Drs. Silverstein and
uy and, as clinicians who are also asked regularly to make difficult
ecisions on behalf of our patients, readily acknowledge the
mportance of clinical trials to establish a platform for evidence-
ased practice. The White Paper devoted to the management of
latelet-directed pharmacotherapy in patients with atherosclerotic
oronary artery disease undergoing elective gastrointestinal proce-
ures (1), although not a guideline document, was intended to
rovide general guidance. Indeed, “bridging therapy” is an impor-
ant topic and an area in great need of randomized data, whether
or patients receiving anticoagulant therapy or those with coronary
rterial stents in whom platelet-directed therapy represents the
tandard of care to minimize life-threatening events, including
tent thrombosis. The rapidly evolving landscape of intravenous
latelet antagonists and oral agents with favorable “onset and
ffset” pharmacodynamic properties, coupled with strong encour-
gement from the clinical community, will undoubtedly provide an
pportunity to undertake in-depth investigation (1).
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